Levothyroxine IV has a half-life of 3-10 days at steady state depending on patient’s intrinsic thyroid function
Chen, Mandy 1; Wang, Shan 1; Hanna, Adel 2
Purpose: Based on the pharmacokinetic profile of levothyroxine, a 3-day hold guideline for adult patients ordered for intravenous (IV) levothyroxine was
The signs and symptoms that suggest thyroid dysfunction are nonspecific and nondiagnostic, especially early in disease presentation; therefore, a diagnosis is
Therapeutic effects last 1-3 weeks after discontinuation1
Economic Evaluation of a Pharmacist-Led 5-Day Therapeutic Hold of IV Levothyroxine at an Academic Medical Center - PMC
An initial intravenous loading dose of Levothyroxine Sodium Injection between 300 to 500 mcg followed by once daily intravenous maintenance doses between 50 and 100 mcg
However, this relative levothyroxine bioavailability information may be critical for other indications such as hypothyroid patients who temporarily cannot take
HHS Author Manuscripts
5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid
excitability (angina, chest pain, palpitations, dysrhythmias)
(1) Important Limitations of Use: The relative bioavailability of this drug has not been established
Many drugs affect thyroid hormone pharmacokinetics TSH is used for the diagnosis of hypothyroidism and evaluation of levothyroxine therapy adequacy with other laboratory and However, data from published literature support the intravenous use of levothyroxine sodium for the
5 mcg/kg/day IV/IM; Use lower starting dose (25 mcg/day) if patient at risk of cardiac failure; if initial serum T4 lower than 5 mcg/dL begin treatment at higher dose (50 mcg/day) Avoid or Use Alternate Drug
Most decisions regarding the methods used for intravenous drug delivery are made by nurses
Levothyroxine is generally taken life-long when used to treat hypothyroidism (low thyroid levels) unless the cause is transient
The management of hypothyroidism concentration off ensuring that patients receive corresponding thyroid harbinger replacement therapy and monitoring ihr response
drug, medical use evaluation, cost effectiveness Assess the venous access device prior, during, and after administering IV push medication for signs and symptoms of complications, such as pain, infiltration, phlebitis, or extravasation
Administer Levothyroxine Sodium Injection as an intravenous injection at a rate not to exceed 100 mcg per minute
Therapy consists of thyroid hormone replacement, unless the hypothyroidism is transient (as after painless thyroiditis or subacute thyroiditis) or reversible (due to a drug that can be discontinued)
Jan 2005;14(1):53-59
Use caution when converting patients from oral to intravenous levothyroxine